Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Martin Allan.
Bioorganic & Medicinal Chemistry Letters | 2009
Martin Allan; Sukhdev Manku; Eric Therrien; Natalie Nguyen; Sylvia Styhler; Marie-France Robert; Anne-Christine Goulet; Andrea J. Petschner; Gabi Rahil; A. Robert MacLeod; Robert Deziel; Jeffrey M. Besterman; Hannah Nguyen; Amal Wahhab
A series of N-benzyl-1-heteroaryl-3-(trifluoromethyl)-1H-pyrazole-5-carboxamides targeting co-activator associated arginine methyltransferase 1 (CARM1) have been designed and synthesized. The potency of these inhibitors was influenced by the nature of the heteroaryl fragment with the thiophene analogues being superior to thiazole, pyridine, isoindoline and benzofuran based inhibitors.
Bioorganic & Medicinal Chemistry Letters | 2009
Eric Therrien; Guillaume Larouche; Sukhdev Manku; Martin Allan; Natalie Nguyen; Sylvia Styhler; Marie-France Robert; Anne-Christine Goulet; Jeffrey M. Besterman; Hannah Nguyen; Amal Wahhab
We have identified the N(1)-benzyl-N(2)-methylethane-1,2-diamine unit as a substitute for the (S)-alanine benzylamide moiety for the design of co-activator associated arginine methyltransferase 1 (CARM1) inhibitors. The potency of these inhibitors is in the same order of magnitude as their predecessors and their clearance, volume of distribution, and half lives were greatly improved.
Bioorganic & Medicinal Chemistry Letters | 2009
Amal Wahhab; David Smil; Alain Ajamian; Martin Allan; Yves Andre Chantigny; Eric Therrien; Natalie Nguyen; Sukhdev Manku; Silvana Leit; Jubrail Rahil; Andrea J. Petschner; Aihua Lu; Alina Nicolescu; Sylvain Lefebvre; Samuel Montcalm; Marielle Fournel; Theresa P. Yan; Zuomei Li; Jeffrey M. Besterman; Robert Deziel
The sulfamide moiety has been utilized to design novel HDAC inhibitors. The potency and selectivity of these inhibitors were influenced both by the nature of the scaffold, and the capping group. Linear long-chain-based analogs were primarily HDAC6-selective, while analogs based on the lysine scaffold resulted in potent HDAC1 and HDAC6 inhibitors.
Bioorganic & Medicinal Chemistry Letters | 2009
Sukhdev Manku; Martin Allan; Natalie Nguyen; Alain Ajamian; Jacques Rodrigue; Eric Therrien; James C. Wang; Tim Guo; Jubrail Rahil; Andrea J. Petschner; Alina Nicolescu; Sylvain Lefebvre; Zuomei Li; Marielle Fournel; Jeffrey M. Besterman; Robert Deziel; Amal Wahhab
We have recently reported on a novel class of histone deacetylase (HDAC) inhibitors bearing a sulfamide group as the zinc-binding unit. Herein, we report on the synthesis of sulfamide based inhibitors designed around a lysine scaffold and their structure-activity relationships against HDAC1 and HDAC6 isotypes as well as 293T cells. Our efforts led us to an improvement of the originally disclosed lysine-based sulfamide, 2a to compound 12h which has equal potency in enzyme and cell-based assays as well as enhanced metabolic stability and PK profile.
Journal of Medicinal Chemistry | 2002
Soon Hyung Woo; Sylvie Frechette; Elie Abou Khalil; Giliane Bouchain; Arkadii Vaisburg; Naomy Bernstein; Oscar Moradei; Silvana Leit; Martin Allan; Marielle Fournel; Marie-Claude Trachy-Bourget; Zuomei Li; Jeffrey M. Besterman; Daniel Delorme
Archive | 2008
Amal Wahhab; Eric Therrien; Martin Allan; Sukhdev Manku
Archive | 2006
Silvana Leit; Amal Wahhab; Martin Allan; David Smil; Pierre Tessier; Robert Deziel; Yves Andre Chantigny
Bioorganic & Medicinal Chemistry Letters | 2004
Arkadii Vaisburg; Naomy Bernstein; Sylvie Frechette; Martin Allan; Elie Abou-Khalil; Silvana Leit; Oscar Moradei; Giliane Bouchain; James Wang; Soon Hyung Woo; Marielle Fournel; Pu T. Yan; Marie-Claude Trachy-Bourget; Ann Kalita; Carole Beaulieu; Zuomei Li; A. Robert MacLeod; Jeffrey M. Besterman; Daniel Delorme
Archive | 2008
Amal Wahhab; Eric Therrien; Martin Allan; Sukhdev Manku
Archive | 2007
David Smil; Silvana Leit; Alain Ajamian; Martin Allan; Yves Andre Chantigny; Robert Deziel; Eric Therrien; Amal Wahhab; Sukhdev Manku